Loading...
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Paz-Ares, L Mezger, J Ciuleanu, T Fischer, J von Pawel, J Provencio, M Kazarnowicz, A Losonczy, G de Castro, G Szczesna, A
Paz-Ares, L
Mezger, J
Ciuleanu, T
Fischer, J
von Pawel, J
Provencio, M
Kazarnowicz, A
Losonczy, G
de Castro, G
Szczesna, A
Citations
Altmetric:
Abstract
Necitumumab is a second-generation recombinant human immunoglobulin G1 EGFR monoclonal antibody that competitively inhibits ligand binding. We aimed to compare necitumumab plus pemetrexed and cisplatin with pemetrexed and cisplatin alone in patients with previously untreated, stage IV, non-squamous non-small-cell lung cancer (NSCLC).
Description
Date
2015-03
Publisher
Collections
Keywords
Type
Article
Citation
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. 2015, 16 (3):328-37 Lancet Oncol